Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Buoyed By Big Offers And Repository of Data, Aurobindo Branches Out Into CRAMS Business With Aurosource

This article was originally published in PharmAsia News

Executive Summary

HYDERABAD, India - Athough a relatively late entrant into the contract research and manufacturing space in India, Aurobindo Pharma with its new logo "Nothing compromised" thinks there is still enough room to forge credible relationships with Western companies for newly floated CRAMS unit Aurosource

You may also be interested in...



With Oxygen Healthcare Buy, India's Piramal Healthcare Breathes More Life Into Its Chemistry Skills

MUMBAI - Flush with $3.72 billion from its much publicized deal struck last year with Abbott Laboratories for its India prescriptions business, Piramal Healthcare is eyeing strategic acquisitions to strengthen its remaining businesses spanning contract research and manufacturing services, OTC drugs and critical care medications

With Oxygen Healthcare Buy, India's Piramal Healthcare Breathes More Life Into Its Chemistry Skills

MUMBAI - Flush with $3.72 billion from its much publicized deal struck last year with Abbott Laboratories for its India prescriptions business, Piramal Healthcare is eyeing strategic acquisitions to strengthen its remaining businesses spanning contract research and manufacturing services, OTC drugs and critical care medications

Pfizer Deal To Help Propel Aurobindo's Revenues To $2 Billion In Three Years

HYDERABAD, India - With fifteen manufacturing sites under its belt and a comprehensive outsourcing deal with Pfizer, India's Aurobindo Pharma expects to see a huge bounce in its revenues from the present $800 million to over $2 billion in a span of three years

Related Content

UsernamePublicRestriction

Register

SC074468

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel